Joo-Chan Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Joo-Chan Kim has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Hee-Sung Park
Department of Chemistry, Korea Advanced Institute of Science and Technology, 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea
4 shared publications - Deokhee Kang
Department of Chemistry Korea Advanced Institute of Science and Technology 291 Daehak-ro, Yuseong-gu Daejeon 34141 Korea
2 shared publications Do-Wook Kim
Department of Chemistry, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
2 shared publications- Do-Wook Kim
Clean Energy Research Center, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea
2 shared publications Jimin Lee
Department of Chemistry, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
2 shared publications- Jin Young Kang
KAIST
2 shared publications
Latest Publications
- Open Access
- 11 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Cryo-EM structure of the LARS1:IARS1 complex reveals a nutrient-responsive switch controlling mTORC1 signaling
Aminoacyl-tRNA synthetases (ARSs) assemble into the multi-tRNA synthetase complex (MSC) to mediate noncanonical functions in cell signaling and stress responses. Among them, human cytosolic leucyl-tRNA synthetase 1 (LARS1) plays a central role in sensing leucine and activating mTORC1, thereby linking nutrient availability to metabolic regulation. Despite recent progress, fundamental questions remain unresolved about the regulatory mechanisms governing LARS1's non-canonical functions, particularly its structural organization within the MSC. Here, we employ an integrated approach combining structural, biochemical, and cellular analyses to investigate the noncanonical roles of LARS1. The cryo-EM structure of the LARS1:isoleucyl-tRNA synthetase 1 (IARS1) complex reveals that LARS1 binds to IARS1, its anchoring partner in the MSC, via its UNE-L domain. Amino acid stimulation induces LARS1 phosphorylation at Ser1070, Ser1077, and Ser1082, which are located at the interface with IARS1. These modifications disrupt the interaction, promote LARS1 dissociation from the MSC, and enable mTORC1 activation. This study highlights phosphorylation as a conserved and critical molecular switch that orchestrates the non-canonical functions of MSC by dynamically modulating the assembly and activity of its components in response to external stimuli.
- 11 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessCryo-EM structure of the LARS1:IARS1 complex reveals a nutrient-responsive switch controlling mTORC1 signaling
Aminoacyl-tRNA synthetases (ARSs) assemble into the multi-tRNA synthetase complex (MSC) to mediate noncanonical functions in cell signaling and stress responses. Among them, human cytosolic leucyl-tRNA synthetase 1 (LARS1) plays a central role in sensing leucine and activating mTORC1, thereby linking nutrient availability to metabolic regulation. Despite recent progress, fundamental questions remain unresolved about the regulatory mechanisms governing LARS1's non-canonical functions, particularly its structural organization within the MSC. Here, we employ an integrated approach combining structural, biochemical, and cellular analyses to investigate the noncanonical roles of LARS1. The cryo-EM structure of the LARS1:isoleucyl-tRNA synthetase 1 (IARS1) complex reveals that LARS1 binds to IARS1, its anchoring partner in the MSC, via its UNE-L domain. Amino acid stimulation induces LARS1 phosphorylation at Ser1070, Ser1077, and Ser1082, which are located at the interface with IARS1. These modifications disrupt the interaction, promote LARS1 dissociation from the MSC, and enable mTORC1 activation. This study highlights phosphorylation as a conserved and critical molecular switch that orchestrates the non-canonical functions of MSC by dynamically modulating the assembly and activity of its components in response to external stimuli.
- Open Access
- 1 September 2025
- Published by Springer Nature in Research Square
Cryo-EM Structure of the LARS1-IARS1 Complex Reveals A Nutrient-Responsive Switch Controlling mTORC1 Signaling
Aminoacyl-tRNA synthetases (ARSs) assemble into the multi-tRNA synthetase complex (MSC) to mediate noncanonical functions in cell signaling and stress responses. Among them, leucyl-tRNA synthetase 1 (LARS1) plays a central role in sensing leucine and activating mTORC1, thereby linking nutrient availability to metabolic regulation. Despite recent progress, fundamental questions remain unresolved about the regulatory mechanisms governing LARS1’s non-canonical functions, particularly its structural organization within the MSC. Here, we employed an integrated approach combining structural, biochemical, and cellular analyses to investigate the noncanonical roles of LARS1. The cryo-EM structure of the LARS1:Isoleucyl-tRNA synthetase 1 (IARS1) complex revealed that LARS1 binds to IARS1, its anchoring partner in the MSC, via its UNE-L domain. Amino acid stimulation induces LARS1 phosphorylation at Ser1070, Ser1077, and Ser1082, which are located at the interface with IARS1. These modifications disrupt the interaction, promote LARS1 dissociation from the MSC, and enable mTORC1 activation. This study highlights phosphorylation as a conserved and critical molecular switch that orchestrates the non-canonical functions of MSC by dynamically modulating the assembly and activity of its components in response to external stimuli.
- 1 September 2025
- Published by Springer Nature in Research Square
Open AccessCryo-EM Structure of the LARS1-IARS1 Complex Reveals A Nutrient-Responsive Switch Controlling mTORC1 Signaling
Aminoacyl-tRNA synthetases (ARSs) assemble into the multi-tRNA synthetase complex (MSC) to mediate noncanonical functions in cell signaling and stress responses. Among them, leucyl-tRNA synthetase 1 (LARS1) plays a central role in sensing leucine and activating mTORC1, thereby linking nutrient availability to metabolic regulation. Despite recent progress, fundamental questions remain unresolved about the regulatory mechanisms governing LARS1’s non-canonical functions, particularly its structural organization within the MSC. Here, we employed an integrated approach combining structural, biochemical, and cellular analyses to investigate the noncanonical roles of LARS1. The cryo-EM structure of the LARS1:Isoleucyl-tRNA synthetase 1 (IARS1) complex revealed that LARS1 binds to IARS1, its anchoring partner in the MSC, via its UNE-L domain. Amino acid stimulation induces LARS1 phosphorylation at Ser1070, Ser1077, and Ser1082, which are located at the interface with IARS1. These modifications disrupt the interaction, promote LARS1 dissociation from the MSC, and enable mTORC1 activation. This study highlights phosphorylation as a conserved and critical molecular switch that orchestrates the non-canonical functions of MSC by dynamically modulating the assembly and activity of its components in response to external stimuli.
- 12 January 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (7) , e202214815
A Versatile Strategy for Screening Custom‐Designed Warhead‐Armed Cyclic Peptide Inhibitors
Demand for peptide‐based pharmaceuticals has been steadily increasing, but only limited success has been achieved to date. To expedite peptide‐based drug discovery, we developed a general scheme for cell‐based screening of cyclic peptide inhibitors armed with a user‐designed warhead. We combined unnatural amino acid incorporation and split intein‐mediated peptide cyclization techniques and integrated a yeast‐based colorimetric screening assay to generate a new scheme that we call the custom‐designed warhead‐armed cyclic peptide screening platform (CWCPS). This strategy successfully discovered a potent inhibitor, CY5‐6Q, that targets human histone deacetylase 8 (HDAC8) with a KD value of 15 nM. This approach can be a versatile and general platform for discovering cyclic peptide inhibitors.
- 12 January 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (7) , e202214815
A Versatile Strategy for Screening Custom‐Designed Warhead‐Armed Cyclic Peptide Inhibitors
Demand for peptide‐based pharmaceuticals has been steadily increasing, but only limited success has been achieved to date. To expedite peptide‐based drug discovery, we developed a general scheme for cell‐based screening of cyclic peptide inhibitors armed with a user‐designed warhead. We combined unnatural amino acid incorporation and split intein‐mediated peptide cyclization techniques and integrated a yeast‐based colorimetric screening assay to generate a new scheme that we call the custom‐designed warhead‐armed cyclic peptide screening platform (CWCPS). This strategy successfully discovered a potent inhibitor, CY5‐6Q, that targets human histone deacetylase 8 (HDAC8) with a KD value of 15 nM. This approach can be a versatile and general platform for discovering cyclic peptide inhibitors.
- 12 January 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (7)
A Versatile Strategy for Screening Custom‐Designed Warhead‐Armed Cyclic Peptide Inhibitors
Demand for peptide‐based pharmaceuticals has been steadily increasing, but only limited success has been achieved to date. To expedite peptide‐based drug discovery, we developed a general scheme for cell‐based screening of cyclic peptide inhibitors armed with a user‐designed warhead. We combined unnatural amino acid incorporation and split intein‐mediated peptide cyclization techniques and integrated a yeast‐based colorimetric screening assay to generate a new scheme that we call the custom‐designed warhead‐armed cyclic peptide screening platform (CWCPS). This strategy successfully discovered a potent inhibitor, CY5‐6Q, that targets human histone deacetylase 8 (HDAC8) with a KD value of 15 nM. This approach can be a versatile and general platform for discovering cyclic peptide inhibitors.
- 12 January 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (7)
A Versatile Strategy for Screening Custom‐Designed Warhead‐Armed Cyclic Peptide Inhibitors
Demand for peptide‐based pharmaceuticals has been steadily increasing, but only limited success has been achieved to date. To expedite peptide‐based drug discovery, we developed a general scheme for cell‐based screening of cyclic peptide inhibitors armed with a user‐designed warhead. We combined unnatural amino acid incorporation and split intein‐mediated peptide cyclization techniques and integrated a yeast‐based colorimetric screening assay to generate a new scheme that we call the custom‐designed warhead‐armed cyclic peptide screening platform (CWCPS). This strategy successfully discovered a potent inhibitor, CY5‐6Q, that targets human histone deacetylase 8 (HDAC8) with a KD value of 15 nM. This approach can be a versatile and general platform for discovering cyclic peptide inhibitors.